Level D· Scientific groundwork from lab and animal studiesNarrative ReviewEurope PMCOpen access

From cold chain to ambient: Benefits, risks, and evidence across cell therapy logistics

Gostage J., Domingo-Lopez DA., Tarpey R., Duffy GP., Levey RE.

Narrative Review on Hip, published in Mol Ther Methods Clin Dev (2025) — summary generated from the PubMed abstract.

Open my reading list
Level D· Scientific groundwork from lab and animal studiesEvidence level of this study

Evidence from laboratory and animal studies provides groundwork for understanding mechanisms and potential before human studies continue.

  • Level A · Stronger Clinical Evidence
  • Level B · Emerging clinical evidence with positive signals
  • Level C · Early human research exploring benefits
  • Level D · Scientific groundwork from lab and animal studies
  • Emerging · Emerging topic under active research
Read the A–D evidence level guide

This page is generated from the PubMed record. The Thai description is an automated summary of bibliographic fields and the abstract, not a full translation, and is not medical advice.

Study type
Narrative Review
Journal
Mol Ther Methods Clin Dev (2025)
Reported sample size
—
Source database
Europe PMC
PMID
41210172
PMCID
PMC12593556
DOI
10.1016/j.omtm.2025.101613
Citations
1

Abstract (original English)

With the exponential growth in the number of cell-based therapies, there is a need to look more closely at a critical factor that unites all these therapies, i.e., cryopreservation, which is currently deemed the gold standard for the storage and shipment of cells. Although cryopreservation is an integral tool in research and clinical practice, it can cause logistical issues (associated with cold chain transport), financial strain, cell dysfunction, and reduced cell viability. Many cell types that are currently being used in cell therapy, or have high clinical potential, have shown to be affected by cryopreservation. Research groups regularly highlight the need for optimized cryopreservation techniques as well as novel alternatives to avoid cryoprotectants. Here, we highlight the potential of ambient cell transport and how, by optimizing three key elements, nutrient, oxygen, and structural support, it may be possible to avoid cryopreservation during cell transport. Ambient cell transport has various benefits including circumventing ultra-low temperatures during shipment, avoidance of cryopreservation-induced cell damage, and offering a more cost-effective and accessible cell transport option. As the cell therapy field evolves, we must actively evolve with it and explore new ways to ensure effective transport of potent, viable, and efficacious cell-based treatments.

What this study does not prove

  • • This study does not prove SVF is an approved treatment or a replacement for standard care.
  • • This is a narrative review: it collects no new patient data and does not systematically appraise evidence quality.

Evidence level

Evidence from laboratory and animal studies provides groundwork for understanding mechanisms and potential before human studies continue.

How we grade evidence

Browse all related research

Filter the research library by this study's title keywords, author, or publication year.

Related research